AbbVie (NYSE: ABBV) has announced that it will be unveiling its third quarter financial results on Wednesday 30th October 2024. The disclosure is planned to occur before market open.
Financial experts on Wall Street anticipate that the establishment is set to announce an estimated $2.92 profit per share for the quarter. Furthermore, the company is expected to disclose a total revenue of $14.28 billion for this specific period.
During the same quarter of the previous year, the company's earnings report indicated a per-share income of $2.95. Moreover, the company generated a total revenue of $13.93 billion during that specific quarter.
The company's full-year performance projections, as provided by Wall Street analysts, suggest a total revenue of $55.72 billion. Further, they expect the earnings per share to achieve profit of $10.85 for the fiscal year.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $2.65 | -8.9% | 14.46 B | +4.3% |
| Q1 2024 | $2.31 | -6.1% | 12.31 B | +0.7% |
| Q4 2023 | $2.79 | -22.5% | 14.30 B | -5.4% |
| Q3 2023 | $2.95 | -19.4% | 13.93 B | -6.0% |
| Q2 2023 | $2.91 | -13.6% | 13.87 B | -4.9% |
| *Growth on year-over-year basis | ||||
Additionally, The company will host a conference call with investors and analysts on 30th October 2024 at 09:00 AM eastern time to review the Q3 2024 financial results.
Monday's trading saw AbbVie (ABBV) shares hit a low of $187.52 and a high of $190.14, with a day volume of 5.38 million shares. The stock closed the regular trading session at $189.68, showing 0.97 percent rise.
